Drug Profile

Buprenorphine buccal tablet - Emplicure AB

Alternative Names: EMPLI-03

Latest Information Update: 09 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Emplicure
Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Clinical Phase Unknown Pain

Most Recent Events

09 Jun 2023 Chemical structure information added
30 Sep 2022 Clinical trials in Pain (In Volunteers) in United Kingdom (Buccal, Tablet)
30 Sep 2022 UK regulatory approves Clinical trial application for buprenorphine in Pain (Emplicure website, December 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com